Dr. Bose received his MD and PhD degrees from the Cornell University-Memorial Sloan-Kettering Cancer Center-Rockefeller University Tri-Institutional MD-PhD program. His doctoral research was performed in the Molecular Pharmacology program at Memorial Sloan-Kettering Cancer Center. Subsequently, he completed Internship and Residency in Internal Medicine at the Washington University School of Medicine and Medical Oncology Fellowship at Johns Hopkins School of Medicine. He is board certified in Internal Medicine and Medical Oncology and he joined the faculty of Washington University School of Medicine in 2007.

Dr. Bose’s research focuses on HER2 positive breast cancer, cancer genomics, and the biochemistry of the HER2/EGFR family of tyrosine kinases. He has been a member of The Cancer Genome Atlas and has co-authored 3 papers in Nature on the genomes of breast or lung cancer. He and his laboratory have identified HER2 activating mutations in HER2 gene amplification negative breast cancer and this led to a successful clinical trial showing that treating HER2 activating mutations with an oral tyrosine kinase inhibitor drug produces tumor regression in metastatic breast cancer patients.